Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.

@article{deMelloSchier2014AntidepressantlikeAA,
  title={Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.},
  author={Alexandre R de Mello Schier and Natalia P de Oliveira Ribeiro and Danielle Sousa Coutinho and Sergio Machado and Oscar Arias-Carri{\'o}n and Jos{\'e} Alexandre S. Crippa and Antonio Waldo Zuardi and Antonio Eg{\'i}dio Nardi and Adriana Cardoso de Oliveira e Silva},
  journal={CNS \& neurological disorders drug targets},
  year={2014},
  volume={13 6},
  pages={
          953-60
        }
}
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of… Expand
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
TLDR
Preliminary clinical trials support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile, and support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders. Expand
Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research
TLDR
A summary of animal-based studies that support the use of CBD as an anxiolytic- and antidepressant-like compound and the putative role of epigenetic mechanisms in mediating CBD’s therapeutic outcomes are provided. Expand
Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action.
TLDR
Findings indicated a therapeutic potential for CBD in the treatment of depression/anxiety associated with diabetes pointing out a complex intrinsic mechanism in which 5-HT1A, CB1, and/or CB2 receptors are differently recruited. Expand
Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
TLDR
Current evidences suggest that CBD has the ability to reduce psychotic, anxiety and withdrawal symptoms by means of several hypothesised pharmacological properties, however, further studies should include larger randomised controlled samples and investigate the impact of CBD on biological measures in order to correlate CBD's clinical effects to potential modifications of neurotransmitters signalling and structural and functional cerebral changes. Expand
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
TLDR
CBD is an useful and promising molecule that may help patients with a number of clinical conditions and should bring important answers in the near future and support the translation of research findings to clinical settings. Expand
Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model.
TLDR
The antidepressant-like effects of periodically administered CBD on the chronic mild stress mouse model are evaluated and are expected to provide a reference for the development of intravenous antidepressant formulations of CBD. Expand
Cannabidiol Modulates the Motivational and Anxiety-Like Effects of 3,4-Methylenedioxypyrovalerone (MDPV) in Mice
TLDR
The results indicate that CBD modulation of MDPV-induced motivational responses in mice varies depending on the requirements of the learning task, resulting in a complex response. Expand
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
TLDR
A comprehensive and up-to-date overview of the molecular basis underlying the therapeutic effects of CBD involved in the treatment of neurological and neuropsychiatric disorders is provided. Expand
Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress
TLDR
The ability of cannabidiol to regulate acute stress hypothalamus-pituitary-adrenal axis activation might be explained, at least in part, by its action on 5-HTR1A receptors. Expand
Cannabidiol as a Potential Treatment for Anxiety Disorders
TLDR
Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
TLDR
Results of this study show that Delta(9)-THC and other cannabinoids exert antidepressant-like actions, and thus may contribute to the overall mood-elevating properties of cannabis. Expand
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
TLDR
The results suggest a potential therapeutical effect of CBD and rimonabant to treat the emotional processing impairment presented in schizophrenia and reinforce the anxiolytic profile of CBD. Expand
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
TLDR
The hypothesis that this cannabinoid has anxiolytic properties is reinforced, as CBD induced an anticonflict effect not mediated by benzodiazepine receptors or by non-specific drug interference on nociceptive threshold or water consumption. Expand
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
TLDR
Future clinical trials involving patients with different anxiety disorders are warranted, especially of panic disorder, obsessive-compulsive disorder, social anxiety disorder, and post-traumatic stress disorders, because of the adequate therapeutic window of CBD. Expand
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
TLDR
It is suggested that CBD reduces anxiety in SAD and that this is related to its effects on activity in limbic and paralimbic brain areas and the effects of this compound on human pathological anxiety and its underlying brain mechanisms. Expand
Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1A receptors
TLDR
The hypothesis that CBD would have antidepressant‐like activity in mice as assessed by the forced swimming test was tested and it was investigated if these responses depended on the activation of 5‐HT1A receptors and on hippocampal expression of brain‐derived neurotrophic factor (BDNF). Expand
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
TLDR
These results give further support to the proposal that BNST is involved in the anxiolytic-like effects of CBD observed after systemic administration, probably by facilitating local 5-HT1A receptor-mediated neurotransmission. Expand
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
TLDR
Findings support that the anxiolytic effect of chronic CBD administration in stressed mice depends on its proneurogenic action in the adult hippocampus by facilitating endocannabinoid-mediated signalling. Expand
Anxiogenic-like effects of chronic cannabidiol administration in rats
TLDR
Chronic administration of CBD produced an anxiogenic-like effect in clear opposition to the acute anxiolytic profile previously reported and decreased the expression of proteins that have been shown to be enhanced by chronic treatment with antidepressant/anxIOlytic drugs. Expand
5‐HT1A receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
TLDR
The hypothesis that CBD would attenuate the autonomic and behavioural consequences of restraint stress (RS) was tested and it was investigated if the responses to CBD depended on activation of 5‐HT1A receptors. Expand
...
1
2
3
4
5
...